Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 20 µg/day levonorgestrel‑releasing intrauterine system for intrauterine use. It provides long‑term contraception and can lessen heavy menstrual bleeding in women of reproductive age through hormonal modulation of the endometrium and cervical mucus.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics and patient safety.

Mirena (levonorgestrel intrauterine system) is used in hormonal contraceptive and menstrual‑management pathways. - Contraception: provides up to five years of highly effective pregnancy prevention. - Heavy menstrual bleeding: reduces menstrual blood loss and may improve anemia. - Endometriosis‑associated pain: alleviates dysmenorrhea and pelvic pain linked to endometriosis.

Adverse reactions to Mirena are reported with varying frequency.

Common Side Effects: - Irregular bleeding or spotting: unpredictable bleeding patterns, especially during the first months. - Decreased menstrual flow or amenorrhea: reduced periods or absence of bleeding. - Headache: mild to moderate intensity. - Breast tenderness: discomfort or soreness in the breasts. - Mood changes: irritability or mood swings. - Abdominal or pelvic pain: cramping or discomfort.

Serious or Rare Side Effects: - Pelvic inflammatory disease: infection of the reproductive organs. - Uterine perforation: rare injury to the uterine wall during insertion. - Ectopic pregnancy: pregnancy occurring outside the uterus. - Expulsion of the device: spontaneous loss of the IUS. - Hormone‑dependent tumor growth: rare stimulation of existing neoplasms.

Before using Mirena, certain precautions and warnings should be considered. - Contraindications: avoid if current pregnancy, active pelvic infection, or known uterine anomalies. - Screening: perform a pelvic exam and ultrasound to confirm uterine size and position. - Follow‑up: schedule a check‑up 4–6 weeks after insertion to verify placement. - Medication interactions: certain enzyme‑inducing drugs may reduce levonorgestrel effectiveness. - Breastfeeding: discuss risks and benefits with a healthcare provider if lactating. - Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel intrauterine system may interact with other medicines that affect hormone levels or uterine environment.

Major Interactions (Avoid): - Enzyme inducers: rifampin, carbamazepine, phenytoin may lower levonorgestrel concentrations. - Antifungal azoles: ketoconazole can increase systemic exposure, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Antiepileptics: valproic acid may alter hormone metabolism. - Antiretrovirals: efavirenz may reduce efficacy. - Herbal supplements: St. John’s wort may decrease hormone levels.